DIRECT is a randomized, open-label, phase III investigational research study that will evaluate the safety and efficacy of daily administration of subcutaneous interferon alfacon-1 plus ribavirin versus no treatment in HCV patients who have not responded to previous combination therapy with pegylated interferon alfa plus ribavirin.